Dr. Horowitz is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
46 Prince St
Ste 301
New Haven, CT 06519Phone+1 203-562-3577Fax+1 203-782-6864
Education & Training
- Yale-New Haven Medical CenterResidency, Surgery, 1979 - 1984
- Columbia University Vagelos College of Physicians and SurgeonsClass of 1979
Certifications & Licensure
- CT State Medical License 1983 - 2024
- American Board of Surgery Surgery
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
- Top MD Consumers Checkbook
- Fellow (FACS) American College of Surgeons
Clinical Trials
- A Randomized Controlled Trial of Routine Shave Margins Versus Standard Partial Mastectomy in Breast Cancer Patients Start of enrollment: 2011 Oct 01
Publications & Presentations
PubMed
- 35 citationsNeoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer.Julia Foldi, Andrea Silber, Emily Reisenbichler, Kamaljeet Singh, Neal A. Fischbach
NPJ Breast Cancer. 2021-02-08 - 304 citationsImpact of Financial Burden of Cancer on Survivors' Quality of Life?Kathleen Fenn, Suzanne B. Evans, Ruth McCorkle, Michael P. DiGiovanna, Lajos Pusztai
Journal of Oncology Practice. 2014-05-27 - 12 citationsCharacteristics and treatment of human epidermal growth factor receptor 2 positive breast cancer: 43,485 cases from the National Cancer Database treated in 2010 and 2011.Brigid K. Killelea, Anees B. Chagpar, Nina R. Horowitz, Donald R. Lannin
American Journal of Surgery. 2017-02-01
Press Mentions
- Connecticut's Top Doctors 2021: Over 1,500 Physicians in 66 SpecialtiesJune 1st, 2021
- Neoadjuvant Durvalumab plus Weekly Nab-Paclitaxel and Dose-Dense doxorubicin/cyclophosphamide in Triple-Negative Breast CancerFebruary 8th, 2021
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: